1062590-01-5Relevant articles and documents
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase
Haile, Pamela A.,Votta, Bartholomew J.,Marquis, Robert W.,Bury, Michael J.,Mehlmann, John F.,Singhaus, Robert,Charnley, Adam K.,Lakdawala, Ami S.,Convery, Máire A.,Lipshutz, David B.,Desai, Biva M.,Swift, Barbara,Capriotti, Carol A.,Berger, Scott B.,Mahajan, Mukesh K.,Reilly, Michael A.,Rivera, Elizabeth J.,Sun, Helen H.,Nagilla, Rakesh,Beal, Allison M.,Finger, Joshua N.,Cook, Michael N.,King, Bryan W.,Ouellette, Michael T.,Totoritis, Rachel D.,Pierdomenico, Maria,Negroni, Anna,Stronati, Laura,Cucchiara, Salvatore,Zió?kowski, Bart?omiej,Vossenk?mper, Anna,MacDonald, Thomas T.,Gough, Peter J.,Bertin, John,Casillas, Linda N.
, p. 4867 - 4880 (2016)
RIP2 kinase is a central component of the innate immune system and enables downstream signaling following activation of the pattern recognition receptors NOD1 and NOD2, leading to the production of inflammatory cytokines. Recently, several inhibitors of R
Compounds and Methods of Treatment
-
Page/Page column 24, (2008/12/08)
A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity.
